Clinical Trials/NCT00328588

NCT00328588

Completed

Phase 2

LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy

Astellas Pharma Inc0 sites37 target enrollmentDecember 2006

ConditionsLung Cancer Cancer of Lung Cancer of the Lung Non-Small Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung

InterventionsYM155

DrugsYM155

Overview

Phase: Phase 2
Intervention: YM155
Conditions: Lung Cancer
Sponsor: Astellas Pharma Inc
Enrollment: 37
Primary Endpoint: Tumor response rate (CR+PR)
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

A study for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients previously treated with chemotherapy.

Registry

clinicaltrials.gov

Start Date

December 2006

End Date

March 2007

Last Updated

18 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Astellas Pharma Inc

Eligibility Criteria

Inclusion Criteria

•Histologically or cytologically confirmed non-small cell lung cancer.
•Prior chemotherapy regimen(s) for lung cancer

Exclusion Criteria

•History of other malignancy in the last 5 years
•Major surgery within the past 21 days

Arms & Interventions

1

7 days continuous infusion

Intervention: YM155

Outcomes

Primary Outcomes

Tumor response rate (CR+PR)

Time Frame: In first 6 cycles

Similar Trials

Completed

Phase 2

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNon Small Cell Lung Cancer

NCT02716311Intergroupe Francophone de Cancerologie Thoracique118

Terminated

Phase 2

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung CancerNon Small Cell Lung Cancer

NCT00509366Duke University101

Recruiting

Phase 1

Pentixafor Positron Emission Tomography Scan: A New Imaging Test for Staging in Non-small Cell Lung Canceron-small cell lung cancerNon-small cell lung cancerCancer - Lung - Non small cell

ACTRN12615001265561Oceanic Molecular Imaging30

Recruiting

Phase 2

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLCNon-small Cell Lung Cancer

NCT05878028Quanli Gao33

Unknown

Phase 2

Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain MetastasesNon Small Cell Lung Cancer Metastatic

NCT03732482Taizhou Hospital400